EUCRISA

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug EUCRISA contains one active pharmaceutical ingredient (API):

1	Crisaborole UNII Q2R47HGR7P - CRISABOROLE
	Crisaborole is an anti-inflammatory benzoxaborole phosphodiesterase-4 (PDE4) inhibitor that suppresses secretion of certain cytokines, such as tumour necrosis factor-α (TNF-α), interleukins (IL-2, IL-4, IL-5), and interferon gamma (IFNγ), and improves skin barrier function as measured by transepidermal water loss (TEWL). It is used for treatment of mild to moderate atopic dermatitis in adults and paediatric patients.
	Read more about Crisaborole

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EUCRISA Ointment	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AH06		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02476991
US	FDA, National Drug Code	55724-211